Statements regarding Nasdaq’s proprietary indexes are not guarantees of future performance. nor any of its affiliates makes any recommendation to buy or sell any financial product or any representation about the financial condition of any company or fund. The information contained above is provided for informational and educational purposes only, and nothing contained herein should be construed as investment advice, either on behalf of a particular financial product or an overall investment strategy. To learn more about the company, technology solutions and career opportunities, visit us on LinkedIn, on Twitter or at Media Contact
Our diverse offering of data, analytics, software, and services enables clients to optimize and execute their business vision with confidence. Nasdaq (Nasdaq: NDAQ) is a global technology company serving the capital markets and other industries. The following 129 securities will be added to the Index: ExchangeĪs a result of the reconstitution, the following 21 securities will be removed from the Index: Exchange The Index is designed to track the performance of a set of securities listed on The Nasdaq Stock Market ® (Nasdaq ®) that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark (ICB).
10, 2021 (GLOBE NEWSWIRE) - Nasdaq (Nasdaq: NDAQ) today announced the results of the annual reconstitution of the Nasdaq Biotechnology Index (Nasdaq: NBI), which will become effective prior to market open on Monday, December 20, 2021.
0 kommentar(er)
